- The FDA approves Alimera’s Iluvien (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME) in patients previously treated with corticosteroids who did not have a significant increase in IOP.
- Allergan’s Ozurdex (dexamethasone intravitreal implant) has had its DME indication expanded by the FDA. Formerly approved for the treatment of DME in pseudophakic adult patients or patients who were scheduled for cataract surgery, Ozurdex is now approved for the general patient population being treated for DME.
- Allergan continues to resist Valeant’s US$54 billion takeover offer. It was in talks to buy specialist pharmaceutical company, Salix, for US$11 billion, wiping out Allergan’s net cash proportion that was so attractive to Valeant, but these talks have ended for now.
- Oculentis is suing Lenstec for infringement of its UK patent for an IOL implant with an enhanced optical blending zone. It is alleged that Lenstec infringed the patent by importing and selling SBL-3 dual-topic IOLs. Oculentis is seeking an injunction against the company, as well as damages and control of the offending products.
